Skip to content
Study details
Enrolling now

HCB301 Trial

FBD Biologics Limited
NCT IDNCT06487624ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

50

Study length

about 1.4 years

Ages

18+

Locations

1 site in SC

What this study is about

This trial is testing a new treatment called HCB301 for advanced solid tumors and relapsed Hodgkin lymphoma. The goal is to see if this medication is safe and effective, and what side effects might occur in adults aged 18 years or older.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take HCB301

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of subjects with MTD and RDE of HCB301., Number/incidence and percentage of subjects with adverse events, including ADA.

Secondary: Area under the plasma concentration versus time curve (AUC) of HCB301, Disease Control Rate (DCR), Duration of Response (DoR), Overall Rate Response (ORR), Peak Plasma Concentration (Cmax) of HCB301, Progression-Free Survival (PFS), Terminal elimination half-life (t1/2) of HCB301, Time to maximum drug concentration in plasma (Tmax) of HCB301

Body systems

Oncology